Live market news
Stocks
IMVT

Immunovant Inc.

IMVTStockUnited States

See in Charts

Latest news on IMVTranked by Oyticker for market impact

72Impact
NegativeMajor information27 Sept 2026 · 00:37 UTC · Global · Short term
IMVT Primary Endpoint Miss Triggers Shareholder Investigation Notice
Immunovant missed a primary endpoint in a clinical trial, causing a ~6% stock decline to multi-year lows on September 23, 2026. A shareholder litigation firm has issued a pending investigation notice.
IMVTBiotechnologyPharmaceuticals

SEC filings

What IMVT filed

All its filings

9 Nov 2026
Quarterly report (opens the document on sec.gov)10-Q
9 Nov 2026
Results announced (opens the document on sec.gov)8-K
3 Sept 2026
Shareholder vote results (opens the document on sec.gov)8-K
6 Aug 2026
Quarterly report (opens the document on sec.gov)10-Q
6 Aug 2026
Results announced (opens the document on sec.gov)8-K
22 Jul 2026
Proxy statement (opens the document on sec.gov)DEF 14A
20 May 2026
Annual report (opens the document on sec.gov)10-K
20 May 2026
Results announced (opens the document on sec.gov)8-K

From SEC EDGAR, the public record of what US-listed companies file. Each document opens on sec.gov.

Oyticker provides market information and analysis for educational purposes. It is not investment advice: you remain responsible for your own decisions.

Latest news on IMVTranked by Oyticker for market impact

IMVT Primary Endpoint Miss Triggers Shareholder Investigation Notice

What IMVT filed